Showing 2901-2910 of 5646 results for "".
- HelpMeSee Eye Surgery Simulator Demonstrations Scheduled for the 2018 World Ophthalmology Conference in Barcelonahttps://modernod.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/HelpMeSee is presenting their Eye Surgery Simulator and companion eBook for teaching manual small incision cataract surgery (MSICS) at the International Council of Ophthalmology’s (ICO) 2018 World Ophthalmology Conference (WOC) in Barcelona, Spain. WOC attendees interested in scheduling dem
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- EyeSouth Announces Strategic Partnership with South Georgia/North Florida Eye Partnershttps://modernod.com/news/eyesouth-announces-strategic-partnership-with-south-georgia-north-florida-eye-partners/2480107/EyeSouth Partners has completed a strategic partnership with South Georgia/North Florida Eye Partners, and Cataract and Laser Surgery Center of South Georgia, expanding its presence into the South Georgia and North Florida regions. EyeSouth is an eye care-focused physician services organization f
- Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticalshttps://modernod.com/news/nicox-announces-research-collaboration-on-novel-ophthalmic-therapeutics-with-ironwood-pharmaceuticals/2480117/Nicox SA announced its entry into a research collaboration with Ironwood Pharmaceuticals focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new
- BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMDhttps://modernod.com/news/biotime-announces-1-9-million-grant-for-continued-development-of-opregen-for-dry-amd/2480136/BioTime has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (IIA). The grant provides funding for the continued development of OpRegen, and to date the IIA has provided annual grants totaling over $13 mil
- First Series C-Round Closing for Medical Device Company Implandata Ophthalmic Productshttps://modernod.com/news/first-series-c-round-closing-for-medical-device-company-implandata-ophthalmic-products/2480150/Ophthalmic medical device company Implandata Ophthalmic Products announced that the company accomplished a first closing of its Series C funding round. The company was able to raise a “mid-single digit million Euro” amount from a strategic and several institutional and private investo
- Bausch + Lomb Initiates Clinical Trial Evaluating New Ophthalmic Viscosurgical Devicehttps://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-ophthalmic-viscosurgical-device/2480163/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new ophthalmic viscosurgical device (OVD). Bausch + Lomb aims to file for premarket approval (PMA) with the FDA at the conclusion of the clinical trial, with plans to bring this next-generation
- Takeda Reaches Deal to Buy Shire for $62 Billionhttps://modernod.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/After several failed attempts, Japanese drugmaker Takeda Pharmaceutical managed to reach an agreement to acquire Shire in a $62 billion deal. The offer is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group. Shire investors will
- Takeda Nears Deal to Buy Shire in Its Biggest Purchasehttps://modernod.com/news/takeda-nears-deal-to-buy-shire-in-its-biggest-purchase/2480167/Takeda Pharmaceutical is nearing an agreement to buy rival drugmaker Shire, people familiar with the matter said, according to a report in Bloomberg. The deal, if appr
- Optos Unveils Monaco Ultra-Widefield Imaging Device with OCT Capabilitieshttps://modernod.com/news/optos-unveils-monaco-ultra-widefield-imaging-device-with-oct-capabilities/2480175/Optos has announced that Monaco, which the company describes as the first ultra-widefield imaging device combined with OCT, was launched Thursday in the United States. Monaco is a compact desk-top UWF retinal imaging device that provides greater imaging functionality and expands the compan